Inducing Remission in Type 1 Diabetes With Alefacept
Status:
Terminated
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to test whether a drug called alefacept will slow or halt
destruction of the beta cells in the pancreas. If the destruction of the beta cells is
stopped, the patients might be able to produce insulin on their own longer, which could stop
or slow the progression of their type 1 diabetes.
This is a multi-center prospective, placebo-controlled, double-blind and randomized trial to
investigate the ability of alefacept to protect residual beta cells from ongoing autoimmune
destruction in adolescents and young adults with newly diagnosed Type 1 Diabetes Mellitus
(T1DM).
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
Immune Tolerance Network (ITN) Juvenile Diabetes Research Foundation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)